Lantern Pharma is advancing ADC development using its RADR® AI platform 

In PLOS One, published study Lantern Pharma’s AI-driven approach identified 82 ADC targets, 290 target-indication pairs, and 729 payload molecules from 50,000+ compounds 

22 targets validated from it for clinical or preclinical settings, 60 novel targets offer potential for IP, portfolio, and licensing potential 

RADR® Platform integrates transcriptomics, proteomics, and mutation profiles across 22 tumor types to identify optimal therapeutic combinations. ADC Payload Potency is GI50 values pM to 10 nM 

Lantern is advancing and enhancing methods and precision approach within its RADR™ AI platform. It is advancing ADC candidates in preclinical development with the MAGICBULLET: Reloaded Initiative., University of Bielefeld

It is actively applying this AI-driven strategy to optimize preclinical ADC candidates

RADR® is ideal for pharma collaborations seeking to accelerate ADC programs or expand with novel targets. It has established a pathway to commercialization through strategic partnerships